Premium
Clinical trials update: highlights of the scientific sessions of the American Heart Association year 2000: Val HeFT, COPERNICUS, MERIT, CIBIS‐II, BEST, AMIOVIRT, V‐MAC, BREATHE, HEAT, MIRACL, FLORIDA, VIVA and the first human cardiac skeletal muscle myoblast transfer for heart failure
Author(s) -
Thackray Simon D.R.,
Witte Klaus K.A.,
Khand Aleem,
Dunn Anita,
Clark Andrew L.,
Cleland John G.F.
Publication year - 2001
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(00)00145-8
Subject(s) - medicine , heart failure , cardiology
This article continues a series of reports summarising recent research developments pertinent to the topic of heart failure. This is a summary of presentations made at scientific sessions of the American Heart Association in November 2000. Clinical studies of particular interest to people caring for patients with heart failure include Val‐HeFT, AMIOVIRT and V‐MAC. New data from β‐blockers trials are reviewed, highlights from some important developments in post‐infarction care, including MIRACL and FLORIDA, discussed and results of some early studies of gene therapy reported.